Biomarker & Intervention Discovery

Deep Vein Thrombosis / Pulmonary Embolism (VTE)

This page lists 10 druggable gene targets, 49 approved or trial-tested drug candidates and 15 recent clinical trials for Deep Vein Thrombosis / Pulmonary Embolism (VTE), with each agent ranked by the strength of its evidence (clinical, mechanistic or correlative). Candidates include existing drugs that could be repurposed. Sources are linked so you can check every claim.

Spontaneous remissionWithout anticoagulation: DVT progresses to PE in 30-50%; massive PE has 30%+ mortality without treatment; spontaneous…
Best-intervention remissionDOACs (rivaroxaban, apixaban): equal or superior efficacy to warfarin with 50% reduction in major bleeding…
Gap sizeModerate — DOACs have largely replaced warfarin; remaining gap is in chronic anticoagulation decision-making and…
Primary barrierpractice
Full remission profile →
Research Tracker Chronic Disease Interventions Deep Vein Thrombosis / Pulmonary Embolism (VTE)

Remission & chronicity

Spontaneous remission
Without anticoagulation: DVT progresses to PE in 30-50%; massive PE has 30%+ mortality without treatment; spontaneous resolution of small PE in 30-40% but recurrence risk high
Best-intervention remission
DOACs (rivaroxaban, apixaban): equal or superior efficacy to warfarin with 50% reduction in major bleeding; catheter-directed thrombolysis for large DVT: rapid thrombus resolution but unclear long-term benefit on PTS (ATTRACT trial); acute massive PE with hemodynamic compromise: systemic thrombolysis reduces mortality 55-65%
Gap size
Moderate — DOACs have largely replaced warfarin; remaining gap is in chronic anticoagulation decision-making and post-VTE care
Primary barrier
practice
DOAC superiority is established but warfarin persistence remains common in patients with mechanical valves (where DOACs are contraindicated) and in some LMIC settings; duration of anticoagulation after unprovoked VTE is an individualised decision poorly standardised; post-thrombotic syndrome (PTS) prevention with compression is rarely implemented

Biomarker Targets & Therapeutic Agents

Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC. Agents ranked: Clinical > Mechanistic > Correlative.

F10 242F11 190F12 187F2 241F5 23PLAT 210PROC 168PROS1 9SERPINC1 35VWF 21

F10

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
FACTOR IX ? unclear Mechanistic DGIdb
SSR-126517E ? unclear Mechanistic DGIdb
COAGULATION FACTOR IX ? unclear Mechanistic DGIdb
COAGULATION FACTOR X HUMAN ? unclear Mechanistic DGIdb
LETAXABAN ? unclear Mechanistic DGIdb
IDRAPARINUX ? unclear Mechanistic DGIdb
COAGULATION FACTOR X, HUMAN ? unclear Mechanistic DGIdb
NADROPARIN CALCIUM ? unclear Mechanistic DGIdb
EDOXABAN ↓ inhibits Mechanistic DGIdb
RIVAROXABAN ↓ inhibits Mechanistic DGIdb
THROMBIN ? unclear Mechanistic DGIdb
LY-517717 ? unclear Mechanistic DGIdb
SR-123781A ? unclear Mechanistic DGIdb
ERIBAXABAN ↓ inhibits Mechanistic DGIdb
TRIMETHOPRIM/SULFADOXINE ? unclear Mechanistic DGIdb
HEPARIN ? unclear Mechanistic DGIdb
APIXABAN ↓ inhibits Mechanistic DGIdb
MANGIFERIN HEPTASULFATE ? unclear Mechanistic DGIdb
DX-9065A ↓ inhibits Mechanistic DGIdb
COAGULATION FACTOR VIIA ? unclear Mechanistic DGIdb
EDOXABAN TOSYLATE ↓ inhibits Mechanistic DGIdb
TANOGITRAN ? unclear Mechanistic DGIdb
2-O, 3-O DESULFATED HEPARIN ? unclear Mechanistic DGIdb
BAY 3389934 ↓ inhibits Mechanistic DGIdb
FACTOR VIII ? unclear Mechanistic DGIdb
SEMULOPARIN ? unclear Mechanistic DGIdb
IDRABIOTAPARINUX SODIUM ↓ inhibits Mechanistic DGIdb
ANDEXANET ALFA ? unclear Mechanistic DGIdb
BEMIPARIN ↓ inhibits Mechanistic DGIdb
VITAMIN K3 ? unclear Mechanistic DGIdb
DAREXABAN ↓ inhibits Mechanistic DGIdb
ANTITHROMBIN III ? unclear Mechanistic DGIdb
FONDAPARINUX ? unclear Mechanistic DGIdb
PROTHROMBIN COMPLEX CONCENTRATE ? unclear Mechanistic DGIdb
DANAPAROID ? unclear Mechanistic DGIdb
GW-813893 ? unclear Mechanistic DGIdb
IDRAPARINUX SODIUM ↓ inhibits Mechanistic DGIdb
BETRIXABAN ↓ inhibits Mechanistic DGIdb
NONACOG ALFA ? unclear Mechanistic DGIdb
EP-217609 ? unclear Mechanistic DGIdb

Showing top 40 of 242 agents ranked by evidence tier.

F11

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
GRUTICIBART ? unclear Mechanistic DGIdb
THROMBIN ALFA ? unclear Mechanistic DGIdb
FESOMERSEN ? unclear Mechanistic DGIdb
ABELACIMAB ? unclear Mechanistic DGIdb
EP-7041 ↓ inhibits Mechanistic DGIdb
MILVEXIAN ↓ inhibits Mechanistic DGIdb
SULFATED PENTAGALLOYLGLUCOSIDE ? unclear Mechanistic 551.0 nM (IC50) DGIdb
OSOCIMAB ? unclear Mechanistic DGIdb
FXIA INHIBITOR 3F ↓ inhibits Mechanistic DGIdb
ALPHA-KETOTHIAZOLE ANALOGUE 36 ↓ inhibits Mechanistic DGIdb
DEXTRAN SULFATE SODIUM ? unclear Mechanistic DGIdb
ANTITHROMBIN III ? unclear Mechanistic DGIdb
HUMAN C1-ESTERASE INHIBITOR ↓ inhibits Mechanistic DGIdb
CHEMBL542434 ↓ inhibits Mechanistic 35000.0 nM (IC50) ChEMBL
CHEMBL206736 ↓ inhibits Mechanistic 1750.0 nM (IC50) ChEMBL
CHEMBL210637 ↓ inhibits Mechanistic 431.0 nM (IC50) ChEMBL
CHEMBL383645 ↓ inhibits Mechanistic 425.0 nM (IC50) ChEMBL
CHEMBL210624 ↓ inhibits Mechanistic 956.0 nM (IC50) ChEMBL
CHEMBL207349 ↓ inhibits Mechanistic 790.0 nM (IC50) ChEMBL
CHEMBL403113 ↓ inhibits Mechanistic 116.0 nM (IC50) ChEMBL
CHEMBL429733 ↓ inhibits Mechanistic 254.0 nM (IC50) ChEMBL
CHEMBL255407 ↓ inhibits Mechanistic 850.0 nM (IC50) ChEMBL
CHEMBL207143 ↓ inhibits Mechanistic 6220.0 nM (IC50) ChEMBL
CHEMBL208289 ↓ inhibits Mechanistic 3310.0 nM (IC50) ChEMBL
CHEMBL207951 ↓ inhibits Mechanistic 713.0 nM (IC50) ChEMBL
CHEMBL382229 ↓ inhibits Mechanistic 2320.0 nM (IC50) ChEMBL
CHEMBL208405 ↓ inhibits Mechanistic 12500.0 nM (IC50) ChEMBL
CHEMBL207453 ↓ inhibits Mechanistic 1200.0 nM (IC50) ChEMBL
CHEMBL208597 ↓ inhibits Mechanistic 1720.0 nM (IC50) ChEMBL
CHEMBL257315 ↓ inhibits Mechanistic 480.0 nM (IC50) ChEMBL
CHEMBL271508 ↓ inhibits Mechanistic 502.0 nM (IC50) ChEMBL
CHEMBL210434 ↓ inhibits Mechanistic 5900.0 nM (IC50) ChEMBL
CHEMBL207052 ↓ inhibits Mechanistic 86000.0 nM (IC50) ChEMBL
CHEMBL210731 ↓ inhibits Mechanistic 2250.0 nM (IC50) ChEMBL
CHEMBL207372 ↓ inhibits Mechanistic 37900.0 nM (IC50) ChEMBL
CHEMBL2448389 ↓ inhibits Mechanistic 77300.0 nM (IC50) ChEMBL
CHEMBL211921 ↓ inhibits Mechanistic 1400.0 nM (IC50) ChEMBL
CHEMBL213434 ↓ inhibits Mechanistic 5900.0 nM (IC50) ChEMBL
CHEMBL215750 ↓ inhibits Mechanistic 7300.0 nM (IC50) ChEMBL
CHEMBL384180 ↓ inhibits Mechanistic 24700.0 nM (IC50) ChEMBL

Showing top 40 of 190 agents ranked by evidence tier.

F12

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
BISMUTH SUBGALLATE ↑ activates Mechanistic DGIdb
GARADACIMAB ? unclear Mechanistic DGIdb
CHEMBL:CHEMBL935 ? unclear Mechanistic DGIdb
BORTEZOMIB ? unclear Mechanistic DGIdb
ANTITHROMBIN III ? unclear Mechanistic DGIdb
METHYL 5-[(4-TERT-BUTYLBENZOYL)AMINO]-2H-1,2,4-TRIAZOLE-3-CARBOXYLATE ↓ inhibits Mechanistic DGIdb
HUMAN C1-ESTERASE INHIBITOR ↓ inhibits Mechanistic DGIdb
ANTI-FXII NANOBODY N4-38 ? unclear Mechanistic DGIdb
CHEMBL107627 ↓ inhibits Mechanistic 61000.0 nM (Ki) ChEMBL
CHEMBL319035 ↓ inhibits Mechanistic 55000.0 nM (Ki) ChEMBL
CHEMBL322165 ↓ inhibits Mechanistic 53000.0 nM (Ki) ChEMBL
CHEMBL107392 ↓ inhibits Mechanistic 52000.0 nM (Ki) ChEMBL
CHEMBL414002 ↓ inhibits Mechanistic 50.0 nM (IC50) ChEMBL
CHEMBL521527 ↓ inhibits Mechanistic 180.0 nM (IC50) ChEMBL
CHEMBL495465 ↓ inhibits Mechanistic 33000.0 nM (IC50) ChEMBL
CHEMBL495155 ↓ inhibits Mechanistic 32000.0 nM (IC50) ChEMBL
CHEMBL495154 ↓ inhibits Mechanistic 10000.0 nM (IC50) ChEMBL
CHEMBL521526 ↓ inhibits Mechanistic 4300.0 nM (IC50) ChEMBL
CHEMBL495153 ↓ inhibits Mechanistic 25000.0 nM (IC50) ChEMBL
CHEMBL494978 ↓ inhibits Mechanistic 9800.0 nM (IC50) ChEMBL
CHEMBL522532 ↓ inhibits Mechanistic 20000.0 nM (IC50) ChEMBL
CHEMBL494808 ↓ inhibits Mechanistic 10000.0 nM (IC50) ChEMBL
CHEMBL502858 ↓ inhibits Mechanistic 32000.0 nM (IC50) ChEMBL
CHEMBL494800 ↓ inhibits Mechanistic 34000.0 nM (IC50) ChEMBL
CHEMBL494798 ↓ inhibits Mechanistic 31000.0 nM (IC50) ChEMBL
CHEMBL495225 ↓ inhibits Mechanistic 30000.0 nM (IC50) ChEMBL
CHEMBL493601 ↓ inhibits Mechanistic 4400.0 nM (IC50) ChEMBL
CHEMBL494799 ↓ inhibits Mechanistic 19000.0 nM (IC50) ChEMBL
CHEMBL494633 ↓ inhibits Mechanistic 24000.0 nM (IC50) ChEMBL
CHEMBL494632 ↓ inhibits Mechanistic 22000.0 nM (IC50) ChEMBL
CHEMBL274376 ↓ inhibits Mechanistic 17000.0 nM (IC50) ChEMBL
CHEMBL494795 ↓ inhibits Mechanistic 42000.0 nM (IC50) ChEMBL
CHEMBL444181 ↓ inhibits Mechanistic 8300.0 nM (IC50) ChEMBL
CHEMBL523874 ↓ inhibits Mechanistic 15000.0 nM (IC50) ChEMBL
CHEMBL495466 ↓ inhibits Mechanistic 23000.0 nM (IC50) ChEMBL
CHEMBL522376 ↓ inhibits Mechanistic 29000.0 nM (IC50) ChEMBL
CHEMBL2448529 ↓ inhibits Mechanistic 1200.0 nM (Ki) ChEMBL
CHEMBL2332605 ↓ inhibits Mechanistic 33500.0 nM (Ki) ChEMBL
CHEMBL2332611 ↓ inhibits Mechanistic 20500.0 nM (Ki) ChEMBL
CHEMBL2332606 ↓ inhibits Mechanistic 11200.0 nM (Ki) ChEMBL

Showing top 40 of 187 agents ranked by evidence tier.

F2

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
DESIRUDIN ↓ inhibits Mechanistic DGIdb
CATECHIN ? unclear Mechanistic DGIdb
BIVALIRUDIN ↓ inhibits Mechanistic DGIdb
ICHORCUMAB ↓ inhibits Mechanistic DGIdb
APRAMIDE A ? unclear Mechanistic DGIdb
ANTITHROMBIN III ? unclear Mechanistic DGIdb
XIMELAGATRAN ↓ inhibits Mechanistic DGIdb
ASPIRIN TRELAMINE ? unclear Mechanistic DGIdb
CHEMBL:CHEMBL586628 ? unclear Mechanistic DGIdb
ATECEGATRAN METOXIL ↓ inhibits Mechanistic DGIdb
WX-UK1 ↓ inhibits Mechanistic DGIdb
ARGATROBAN ↓ inhibits Mechanistic DGIdb
ODIPARCIL ? unclear Mechanistic DGIdb
HIRUDIN ? unclear Mechanistic DGIdb
DABIGATRAN ↓ inhibits Mechanistic DGIdb
VITAMIN K3 ? unclear Mechanistic DGIdb
ANISINDIONE ? unclear Mechanistic DGIdb
ANTITHROMBIN ALFA ↓ inhibits Mechanistic DGIdb
MELAGATRAN ↓ inhibits Mechanistic 4700.0 nM (IC50) DGIdb
PYRIDOXAL PHOSPHATE ANHYDROUS ? unclear Mechanistic DGIdb
AZD-8165 ? unclear Mechanistic DGIdb
DPOC-4088 ? unclear Mechanistic DGIdb
TAMOXIFEN ? unclear Mechanistic DGIdb
DUP-714 ↓ inhibits Mechanistic DGIdb
BAY 3389934 ↓ inhibits Mechanistic DGIdb
PROTHROMBIN COMPLEX CONCENTRATE ? unclear Mechanistic DGIdb
PEGMUSIRUDIN ? unclear Mechanistic DGIdb
DABIGATRAN ETEXILATE MESYLATE ↓ inhibits Mechanistic DGIdb
DEFIBROTIDE ↓ inhibits Mechanistic DGIdb
PROTHROMBIN ? unclear Mechanistic DGIdb
HEPARIN ? unclear Mechanistic DGIdb
SR-123781A ? unclear Mechanistic DGIdb
CYANIN ? unclear Mechanistic DGIdb
BORTEZOMIB ? unclear Mechanistic 13000.0 nM (Ki) DGIdb
AZ12971554 ↓ inhibits Mechanistic DGIdb
ENOXAPARIN SODIUM ? unclear Mechanistic DGIdb
AVATROMBOPAG ? unclear Mechanistic DGIdb
SILIBININ ? unclear Mechanistic DGIdb
QUERCETIN ? unclear Mechanistic DGIdb
LUSUTROMBOPAG ? unclear Mechanistic DGIdb

Showing top 40 of 241 agents ranked by evidence tier.

F5

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
AVATROMBOPAG ? unclear Mechanistic DGIdb
ASPARAGINASE ? unclear Mechanistic DGIdb
ELTROMBOPAG ? unclear Mechanistic DGIdb
LUSUTROMBOPAG ? unclear Mechanistic DGIdb
DROTRECOGIN ALFA ↓ inhibits Mechanistic DGIdb
THROMBIN ? unclear Mechanistic DGIdb
OSIMERTINIB ? unclear Mechanistic DGIdb
TAMOXIFEN ? unclear Mechanistic DGIdb
RIVAROXABAN ? unclear Mechanistic DGIdb
DROTRECOGIN ALFA (ACTIVATED) ? unclear Mechanistic Open Targets
CHEMBL381949 ↓ inhibits Mechanistic 15000.0 nM (Ki) ChEMBL
CHEMBL379036 ↓ inhibits Mechanistic 13000.0 nM (Ki) ChEMBL
CHEMBL436766 ↓ inhibits Mechanistic 5700.0 nM (Ki) ChEMBL
RAZAXABAN ↓ inhibits Mechanistic 19700.0 nM (Ki) ChEMBL
CHEMBL259312 ↓ inhibits Mechanistic 18600.0 nM (IC50) ChEMBL
CHEMBL1162108 ↓ inhibits Mechanistic 1810.0 nM (IC50) ChEMBL
CHEMBL1162109 ↓ inhibits Mechanistic 3800.0 nM (IC50) ChEMBL
CHEMBL261865 ↓ inhibits Mechanistic 38050.0 nM (IC50) ChEMBL
CHEMBL1162110 ↓ inhibits Mechanistic 40570.0 nM (IC50) ChEMBL
CHEMBL1614804 ↓ inhibits Mechanistic 32400.0 nM (IC50) ChEMBL
CHEMBL410426 ↓ inhibits Mechanistic 8950.0 nM (IC50) ChEMBL
CHEMBL265687 ↓ inhibits Mechanistic 9190.0 nM (IC50) ChEMBL
CHEMBL410427 ↓ inhibits Mechanistic 62900.0 nM (IC50) ChEMBL

PLAT

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
ATORVASTATIN CALCIUM TRIHYDRATE ? unclear Mechanistic DGIdb
PAMITEPLASE ? unclear Mechanistic DGIdb
ALTEPLASE ? unclear Mechanistic DGIdb
6-AMINOCAPROIC ACID ↓ inhibits Mechanistic DGIdb
MELPHALAN ? unclear Mechanistic DGIdb
NAPROXEN SODIUM ? unclear Mechanistic DGIdb
BORTEZOMIB ? unclear Mechanistic DGIdb
TRANEXAMIC ACID ? unclear Mechanistic DGIdb
DUP-714 ↓ inhibits Mechanistic DGIdb
RETEPLASE ? unclear Mechanistic DGIdb
TENECTEPLASE ? unclear Mechanistic DGIdb
DUTEPLASE ? unclear Mechanistic DGIdb
ORAL CONTRACEPTIVE ? unclear Mechanistic DGIdb
RECOMBINANT LYMPHOKINE ? unclear Mechanistic DGIdb
EPOETIN ALFA ? unclear Mechanistic DGIdb
RALOXIFENE HYDROCHLORIDE ? unclear Mechanistic DGIdb
UROKINASE ? unclear Mechanistic DGIdb
LANOTEPLASE ? unclear Mechanistic DGIdb
MONTEPLASE ? unclear Mechanistic DGIdb
CHEMBL105819 ↓ inhibits Mechanistic 0.7 nM (IC50) ChEMBL
EFEGATRAN ↓ inhibits Mechanistic 34.0 nM (IC50) ChEMBL
CHEMBL55155 ↓ inhibits Mechanistic 52000.0 nM (Ki) ChEMBL
CHEMBL53448 ↓ inhibits Mechanistic 71500.0 nM (Ki) ChEMBL
CHEMBL300030 ↓ inhibits Mechanistic 65900.0 nM (Ki) ChEMBL
CHEMBL55653 ↓ inhibits Mechanistic 53800.0 nM (Ki) ChEMBL
CHEMBL54894 ↓ inhibits Mechanistic 60100.0 nM (Ki) ChEMBL
CHEMBL297835 ↓ inhibits Mechanistic 18000.0 nM (IC50) ChEMBL
CHEMBL135723 ↓ inhibits Mechanistic 120.0 nM (Ki) ChEMBL
CHEMBL96433 ↓ inhibits Mechanistic 35.0 nM (Ki) ChEMBL
CHEMBL96493 ↓ inhibits Mechanistic 63000.0 nM (Ki) ChEMBL
CHEMBL93269 ↓ inhibits Mechanistic 25000.0 nM (Ki) ChEMBL
CHEMBL92251 ↓ inhibits Mechanistic 280.0 nM (Ki) ChEMBL
CHEMBL48608 ↓ inhibits Mechanistic 460.0 nM (Ki) ChEMBL
CHEMBL327789 ↓ inhibits Mechanistic 14000.0 nM (Ki) ChEMBL
CHEMBL52427 ↓ inhibits Mechanistic 110.0 nM (Ki) ChEMBL
CHEMBL92277 ↓ inhibits Mechanistic 46000.0 nM (Ki) ChEMBL
CHEMBL327715 ↓ inhibits Mechanistic 1000.0 nM (Ki) ChEMBL
CHEMBL328772 ↓ inhibits Mechanistic 380.0 nM (Ki) ChEMBL
CHEMBL92883 ↓ inhibits Mechanistic 160.0 nM (Ki) ChEMBL
CHEMBL330244 ↓ inhibits Mechanistic 3400.0 nM (Ki) ChEMBL

Showing top 40 of 210 agents ranked by evidence tier.

PROC

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
LUSUTROMBOPAG ? unclear Mechanistic DGIdb
PROTHROMBIN COMPLEX CONCENTRATE ? unclear Mechanistic DGIdb
PROTEIN C CONCENTRATE (HUMAN) ? unclear Mechanistic DGIdb
PROGESTERONE ? unclear Mechanistic DGIdb
WARFARIN ? unclear Mechanistic DGIdb
VITAMIN K3 ? unclear Mechanistic DGIdb
ESTRADIOL VALERATE ? unclear Mechanistic DGIdb
COMPOUND 37 [PMID: 24418773] ↓ inhibits Mechanistic DGIdb
ANCROD ? unclear Mechanistic DGIdb
SYNTHETIC CONJUGATED ESTROGENS, A ? unclear Mechanistic DGIdb
AVATROMBOPAG ? unclear Mechanistic DGIdb
3K3A-ACTIVATED PROTEIN C ? unclear Mechanistic DGIdb
SODIUM TETRADECYL SULFATE ? unclear Mechanistic DGIdb
CHEMBL133326 ↓ inhibits Mechanistic 23000.0 nM (IC50) ChEMBL
CHEMBL559015 ↓ inhibits Mechanistic 1800.0 nM (Ki) ChEMBL
CHEMBL432306 ↓ inhibits Mechanistic 3700.0 nM (IC50) ChEMBL
CHEMBL330572 ↓ inhibits Mechanistic 5200.0 nM (Ki) ChEMBL
CHEMBL92530 ↓ inhibits Mechanistic 18000.0 nM (Ki) ChEMBL
CHEMBL93854 ↓ inhibits Mechanistic 1970.0 nM (Ki) ChEMBL
CHEMBL431267 ↓ inhibits Mechanistic 11000.0 nM (Ki) ChEMBL
CHEMBL96218 ↓ inhibits Mechanistic 9500.0 nM (Ki) ChEMBL
CHEMBL85757 ↓ inhibits Mechanistic 12000.0 nM (Ki) ChEMBL
CHEMBL328893 ↓ inhibits Mechanistic 8000.0 nM (Ki) ChEMBL
CHEMBL431281 ↓ inhibits Mechanistic 4200.0 nM (Ki) ChEMBL
CHEMBL93151 ↓ inhibits Mechanistic 5500.0 nM (Ki) ChEMBL
CHEMBL107627 ↓ inhibits Mechanistic 13500.0 nM (Ki) ChEMBL
CHEMBL107911 ↓ inhibits Mechanistic 94000.0 nM (Ki) ChEMBL
CHEMBL107282 ↓ inhibits Mechanistic 39000.0 nM (Ki) ChEMBL
CHEMBL319035 ↓ inhibits Mechanistic 33000.0 nM (Ki) ChEMBL
CHEMBL322901 ↓ inhibits Mechanistic 12000.0 nM (Ki) ChEMBL
CHEMBL322165 ↓ inhibits Mechanistic 10300.0 nM (Ki) ChEMBL
CHEMBL107392 ↓ inhibits Mechanistic 15200.0 nM (Ki) ChEMBL
CHEMBL352039 ↓ inhibits Mechanistic 6000.0 nM (IC50) ChEMBL
CHEMBL70328 ↓ inhibits Mechanistic 15000.0 nM (Ki) ChEMBL
CHEMBL98472 ↓ inhibits Mechanistic 6560.0 nM (IC50) ChEMBL
CHEMBL98858 ↓ inhibits Mechanistic 73000.0 nM (IC50) ChEMBL
CHEMBL327600 ↓ inhibits Mechanistic 1200.0 nM (Ki) ChEMBL
CHEMBL93796 ↓ inhibits Mechanistic 7000.0 nM (Ki) ChEMBL
CHEMBL331943 ↓ inhibits Mechanistic 2400.0 nM (Ki) ChEMBL
DABIGATRAN ↓ inhibits Mechanistic 20930.0 nM (Ki) ChEMBL

Showing top 40 of 168 agents ranked by evidence tier.

PROS1

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
PROTHROMBIN COMPLEX CONCENTRATE ? unclear Mechanistic DGIdb
WARFARIN ? unclear Mechanistic DGIdb
PROGESTERONE ? unclear Mechanistic DGIdb
VITAMIN K3 ? unclear Mechanistic DGIdb
ESTRADIOL VALERATE ? unclear Mechanistic DGIdb
LUSUTROMBOPAG ? unclear Mechanistic DGIdb
PROTEIN S HUMAN ? unclear Mechanistic DGIdb
AVATROMBOPAG ? unclear Mechanistic DGIdb
SYNTHETIC CONJUGATED ESTROGENS, A ? unclear Mechanistic DGIdb

SERPINC1

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
PROGESTERONE ? unclear Mechanistic DGIdb
FONDAPARINUX ↑ activates Mechanistic DGIdb
PARNAPARIN SODIUM ↑ activates Mechanistic DGIdb
HEPARIN CALCIUM ? unclear Mechanistic DGIdb
LUSUTROMBOPAG ? unclear Mechanistic DGIdb
SULODEXIDE ? unclear Mechanistic DGIdb
ESTRADIOL VALERATE ? unclear Mechanistic DGIdb
AVATROMBOPAG ? unclear Mechanistic DGIdb
DOCIPARSTAT SODIUM ? unclear Mechanistic DGIdb
DELPARANTAG ? unclear Mechanistic DGIdb
DANAPAROID ↑ activates Mechanistic DGIdb
GEMCITABINE ? unclear Mechanistic DGIdb
2-O, 3-O DESULFATED HEPARIN ? unclear Mechanistic DGIdb
ENOXAPARIN SODIUM ↑ activates Mechanistic DGIdb
HEPARIN ↑ activates Mechanistic DGIdb
BEMIPARIN SODIUM ↑ activates Mechanistic DGIdb
SYNTHETIC CONJUGATED ESTROGENS, A ? unclear Mechanistic DGIdb
SEMULOPARIN SODIUM ↓ inhibits Mechanistic DGIdb
UNFRACTIONATED HEPARIN ? unclear Mechanistic DGIdb
TINZAPARIN SODIUM ↑ activates Mechanistic DGIdb
HEPARIN SODIUM ↑ activates Mechanistic DGIdb
CARBOPLATIN ? unclear Mechanistic DGIdb
NADROPARIN CALCIUM ↑ activates Mechanistic DGIdb
ELTROMBOPAG ? unclear Mechanistic DGIdb
ANTITHROMBIN ALFA ? unclear Mechanistic DGIdb
FONDAPARINUX SODIUM ? unclear Mechanistic Open Targets
DANAPAROID SODIUM ? unclear Mechanistic Open Targets
CHEMBL609990 ↓ inhibits Mechanistic 58.0 nM (Kd) ChEMBL
CHEMBL1909451 ↓ inhibits Mechanistic 7.0 nM (Kd) ChEMBL
CHEMBL2303814 ↓ inhibits Mechanistic 2.8 nM (Kd) ChEMBL
CHEMBL2303815 ↓ inhibits Mechanistic 1.9 nM (Kd) ChEMBL
CHEMBL51173 ↓ inhibits Mechanistic 570.0 nM (IC50) ChEMBL
IDRAPARINUX SODIUM ↓ inhibits Mechanistic 1.0 nM (Kd) ChEMBL
DALTEPARIN SODIUM ? unclear Clinical Open Targets
FITUSIRAN ? unclear Clinical Open Targets

VWF

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
EGAPTIVON PEGOL ↓ inhibits Mechanistic DGIdb
PHENYLEPHRINE HYDROCHLORIDE ? unclear Mechanistic DGIdb
DA-697B ? unclear Mechanistic DGIdb
HEPARIN ? unclear Mechanistic DGIdb
THALIDOMIDE ? unclear Mechanistic DGIdb
PENTOXIFYLLINE ? unclear Mechanistic DGIdb
WARFARIN ? unclear Mechanistic DGIdb
VINCRISTINE ? unclear Mechanistic DGIdb
VONICOG ALFA ? unclear Mechanistic DGIdb
CAPLACIZUMAB ↓ inhibits Mechanistic DGIdb
STREPTOZOCIN ? unclear Mechanistic DGIdb
O-CHLOROACETYLCARBAMOYLFUMAGILLOL ? unclear Mechanistic DGIdb
RIBAVIRIN ? unclear Mechanistic DGIdb
VON WILLEBRAND FACTOR HUMAN ? unclear Mechanistic DGIdb
METHYLENE BLUE ANHYDROUS ? unclear Mechanistic DGIdb
TYROSINE KINASE INHIBITOR ? unclear Mechanistic DGIdb
PREDNISONE ? unclear Mechanistic DGIdb
MITOMYCIN ANTINEOPLASTIC ANTIBIOTIC ? unclear Mechanistic DGIdb
VITAMIN B6 ? unclear Mechanistic DGIdb
ACETYLCYSTEINE ? unclear Mechanistic DGIdb
FACTOR VIII ? unclear Mechanistic DGIdb

Clinical Trials

Drug, biologic and supplement trials (treatment or prevention) from ClinicalTrials.gov whose main condition is Deep Vein Thrombosis / Pulmonary Embolism (VTE): recruiting, active or completed, most recently updated first. Data retrieved 2026-10-28.

REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants Recruiting
NCT07213778 Phase: 3 Started: 2025-11-24

This study is researching an experimental drug called REGN7508 (called "study drug") and how it compares against another treatment called Acetylsalicylic Acid (ASA). The study is focused on adults undergoing elective, unilateral (one side) total knee replacement surgery. The aim of the study is to s...

Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Cancers Recruiting
NCT07493304 Phase: 3 Started: 2026-08-26

This study is researching an experimental drug called REGN7508 (called "study drug") and will consist of 2 parts: Part 1 and Part 2. The study is focused on participants with or without cancer who develop blood clots in certain veins (called Deep Vein Thrombosis \[DVT\]) that block blood flow (Part ...

The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Venous Thromboembolism (DANNOAC-VTE) Active Not Recruiting
NCT03129555 Phase: 4 Started: 2023-04-01

No randomized head-to-head comparison between the individual Non-vitamin K Antagonist Oral Anticoagulants (NOAC) exists. The DANNOAC-VTE study is a nationwide cluster randomized cross-over study comparing efficacy and safety of the four NOACs, edoxaban, apixaban, rivaroxaban and dabigatran for oral ...

Hokusai Study in Pediatric Patients With Confirmed Venous Thromboembolism (VTE) Completed
NCT02798471 Phase: 3 Started: 2017-03-27

This is an event driven Phase 3, prospective, randomized, open-label, blinded endpoint evaluation (PROBE) parallel group study in subjects with confirmed VTE. This study is designed to evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of edoxaban and to compare the efficacy and safety of ...

Apixaban in Thrombocytopenia Recruiting
NCT06886516 Phase: Early 1 Started: 2025-02-28

This study is being done to determine the feasibility and safety of using a novel dose adjusted apixaban for the management of participants with cancer-associated venous thromboembolism (blood clot) or and thrombocytopenia (low number of platelets in the blood). Investigators are also looking to see...

Therapeutic Initial Heparin Dosing for Patients With Clots or Certain Heart Conditions Admitted to the Hospital Active Not Recruiting
NCT07250763 Phase: 4 Started: 2023-09-20

The goal of this clinical trial study is to test whether a mathematical calculation, using the patient's gender, weight and kidney function, can better predict a patient's heparin goal dose than a flat number of units per patient weight can. Participants will have the first dose of heparin infusion ...

Extended-Duration Low-Intensity Apixaban to Prevent Recurrence in High-Risk Patients With Provoked Venous Thromboembolism Completed
NCT04168203 Phase: 4 Started: 2021-03-01

Design: U.S.-based, single-center, randomized placebo-controlled trial. Brief Treatment Description: Low-intensity apixaban (2.5mg twice daily) for extended-duration secondary prevention of VTE after initial treatment for provoked VTE. Purpose: To establish the safety and efficacy of low-intensity a...

Evaluation of Anti-Xa Levels in Surgery Patients Receiving Weight-based Heparin Completed
NCT03516656 Phase: Early 1 Started: 2018-03-23

The purpose of this study is to determine if weight-based heparin infusions at a rate of 10 units/kg/hour are sufficient to maintain a target anti-Xa of 0.1-0.35 IU/mL for VTE prophylaxis in patients undergoing microvascular surgery. Additionally, a pilot protocol has been developed to titrate these...

REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults Recruiting
NCT07015905 Phase: 3 Started: 2025-06-25

This study is researching an experimental drug called REGN7508 (called "study drug"). The study is focused on adults undergoing elective, unilateral (one side) total knee replacement surgery. The aim of the study is to see how effective the study drug is at preventing Venous Thromboembolism (VTE) an...

Short-term Low-dose Low-molecular-weight Heparin to Prevent Postpartum Thrombosis Recruiting
NCT07140211 Phase: 3 Started: 2025-10-15

The goal of this clinical trial is to evaluate the risk-benefit of a short-term treatment with a low-dose low-molecular-weight heparin (LMWH), in the postpartum period (after delivery). The main questions it aims to answer are: * compared to no treatment, does short-term postpartum LMWH modify the r...

Venous Thromboembolism (VTE) Prophylaxis With REGN7508 and REGN9933 in Adult and Adolescent Participants With a Peripherally Inserted Central Catheter (PICC) Recruiting
NCT07697599 Phase: 3 Started: 2026-09-07

This study is researching 2 different experimental drugs called REGN7508 and REGN9933 (called "study drugs"). The study is focused on people who have a tube placed in a vein to receive treatment (called Peripherally Inserted Central Catheter \[PICC\]). Patients with PICCs have a higher risk of getti...

A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Profile of YKYY033 Injection Recruiting
NCT07786779 Phase: 1 Started: 2026-07-10

A phase 1 study to evaluate the safety and tolerability of a single administration of YKYY033 injection in healthy adult participants

Bleeding Risk With Apixaban Versus Rivaroxaban in Acute Pulmonary Embolism Completed
NCT07774273 Phase: N/A Started: 2021-01-01

This prospective, open-label, randomized controlled trial will compare clinically relevant bleeding during the first three months of treatment with apixaban versus rivaroxaban in adults with acute pulmonary embolism (PE) in a Pakistani cohort. A total of 540 participants will be randomized 1:1 to re...

Prevention of Postpartum Venous Thromboembolism in Women at Intermediate Risk Recruiting
NCT06845423 Phase: 4 Started: 2025-05-16

Venous thromboembolism (VTE) is currently the second cause of death in women of reproductive age worldwide. The incidence of VTE during pregnancy is 1.2 to 1.4/1000 women, half of VTE occurring during postpartum and as PE in majority of cases, accounting for 8.8% of maternal deaths. Majority of post...

Efficacy of Aspirin in Preventing Venous Thromboembolism Completed
NCT06635317 Phase: 4 Started: 2022-04-24

Efficacy of aspirin and enoxaparin in preventing venous tromboembolism was compared after total knee or hip arthroplasty.

Agents Found By Disease-Level Search

Searched directly from “Deep Vein Thrombosis / Pulmonary Embolism (VTE)” via ClinicalTrials.gov interventions and Open Targets' disease→drug data — independent of the 10-gene target panel above. This surfaces agents whose mechanism doesn't route through a curated gene (combination therapies, standard-of-care drugs, targets outside the panel).

49 agents shown (approved or with trial evidence) — 42 not found by the gene-target search above.

EnoxaparinNOT in gene-target list

Phase 3 · 7 trials · source: ClinicalTrials.gov, Open Targets
NCT00097357 NCT01354704 NCT03276143

Rivaroxaban

Approved · 4 trials · source: ClinicalTrials.gov, Open Targets
NCT02486445 NCT07618988 NCT01708850

Apixaban

Approved · 4 trials · source: ClinicalTrials.gov, Open Targets
NCT00097357 NCT03276143 NCT01780987

DU-176bNOT in gene-target list

· 4 trials · source: ClinicalTrials.gov
NCT01203072 NCT01203072 NCT01203072

Warfarin

Phase 3 · 3 trials · source: ClinicalTrials.gov, Open Targets
NCT00097357 NCT01780987 NCT00740493

Fondaparinux sodium

Approved · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT00843492 NCT00531843

darexaban (YM150)NOT in gene-target list

· 2 trials · source: ClinicalTrials.gov
NCT01028950 NCT00942435

rivaroxaban 2.5 mg bid + aspirin 100 mgNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06873321

clopidogrel 75 mg od for 3 months followed by aspirin 100 mg od for endovascular procedures or aspirin for open proceduresNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06873321

NadroparinNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00843492

Enoxaparin PlaceboNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00097357

Apixaban PlaceboNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00097357

Real time heparin dose adjustmentNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02970032

Standard heparin doseNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02970032

osocimab (BAY1213790)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03276143

PICC and MidlineNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02489721

AspirinNOT in gene-target list

Phase 2/3 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT06494878

Low-molecular-weight heparinNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06494878

Blood draw (Visit 1)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04583878

Blood draw (Visits 2 and 3)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04583878

AlertNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00853463

alteplase (recombinant t-PA)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03672006

Heparin

Phase 3 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT03672006

Bemiparin

Phase 2 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT00219973

Fondaparinux

Phase 3 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT00894283

EVLTNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03041805

RFANOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03041805

USFSNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03041805

HL/strippingNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03041805

MiniphlebectomyNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03041805

SclerotherapyNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03041805

GCSNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03041805

LMWHNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03041805

dabigatran etexilate 150 mg twice daily (BID)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00558259

Tranexamic acid injectionNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04986813

Firstly : Amoxicillin-Clavulanic acid and secondly : PlaceboNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00603317

Firstly : Placebo and secondly : Amoxicillin-Clavulanic acidNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00603317

Low dose nadroparinNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01828697

Intermediate dose nadroparinNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01828697

Low dose enoxaparinNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01828697

Intermediate dose enoxaparinNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01828697

Low dose dalteparinNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01828697

Intermediate dose dalteparinNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01828697

Fixed low dose tinzaparinNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01828697

Intermediate dose tinzaparinNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01828697

dalteparinNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00135876

warfarin accordingly INR valueNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00623987

Percutaneous mechanical thrombectomy with profunda femoris vein thrombosis clearance (PMT with PFV-TC)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07622199

Percutaneous mechanical thrombectomy without profunda femoris vein thrombosis clearance (PMT without PFV-TC)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07622199

Generated by the Open Source Medicine Foundation Biomarker Pipeline — 2026-10-08. Data sources: DGIdb, Open Targets, ChEMBL, PubMed, ClinicalTrials.gov. Not medical advice.